Head-to-head evidence
Salbutamol HFA-152a vs Ventolin
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Asthma
Shared mechanism: Beta-2 adrenergic receptor · full Asthma pipeline
Salbutamol HFA-152a
Developed by GlaxoSmithKline
NCT06261957 · Phase 3 · completed
The trial randomized 477 participants and used quadruple blinding with an active salbutamol comparator. Its primary clinical safety endpoint was the number of participants with adverse events, but results are not posted, so whether the primary comparison was favorable cannot be determined.
Next expected readout: February 2027 · NCT06433921 (registry estimate)
Ventolin
Developed by GlaxoSmithKline
NCT01076322 · Phase 3 · completed
The study randomized participants to treatment sequences and included Ventolin as the active comparator, but it was open-label and small, with an estimated 17 participants. Its primary endpoint, change in FEV1, is a clinical lung-function measure, but no results are posted to show whether the comparison was favorable for Ventolin or met its prespecified objective.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Salbutamol HFA-152a's landscape · Ventolin's landscape